CDNACareDx, Inc.

Nasdaq caredx.com


$ 23.67 $ 0.81 (3.54 %)    

Monday, 05-Aug-2024 15:59:56 EDT
QQQ $ 437.97 $ -13.38 (-2.98 %)
DIA $ 386.91 $ -10.32 (-2.6 %)
SPY $ 518.58 $ -15.52 (-2.91 %)
TLT $ 98.76 $ 0.52 (0.53 %)
GLD $ 222.59 $ -2.86 (-1.27 %)
$ 23.69
$ 23.67 x 100
-- x --
-- - --
$ 4.80 - $ 26.50
1,544,099
na
1.24B
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-24-2022 12-31-2021 10-K
12 10-28-2021 09-30-2021 10-Q
13 07-29-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 10-29-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 04-30-2020 03-31-2020 10-Q
19 02-28-2020 12-31-2019 10-K
20 10-31-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-06-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-22-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 06-09-2017 03-31-2017 10-Q
31 04-21-2017 12-31-2016 10-K
32 11-15-2016 09-30-2016 10-Q
33 08-22-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-29-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-31-2015 12-31-2014 10-K
40 11-14-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 goldman-sachs-maintains-buy-on-caredx-raises-price-target-to-26

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $16 to $26.

 craig-hallum-maintains-buy-on-caredx-raises-price-target-to-32

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $22 to $32.

 hc-wainwright--co-reiterates-neutral-on-caredx

HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.

 caredx-q2-2024-adj-eps-025-beats-014-estimate-sales-92274m-beat-67861m-estimate

CareDx (NASDAQ:CDNA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(0.14) by 278...

 where-caredx-stands-with-analysts
Where CareDx Stands With Analysts
07/17/2024 16:00:38

 goldman-sachs-maintains-buy-on-caredx-raises-price-target-to-16

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $14 to $16.

 hc-wainwright--co-reiterates-neutral-on-caredx

HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.

 caredx-to-present-new-data-at-the-2024-american-transplant-congress-being-held-june-1-5-in-philadelphia

CareDx solutions are featured in 36 oral presentations and posters, and a symposium. The findings highlight innovative approach...

Core News & Articles

CareDx Reiterates Position that it Does Not Infringe Natera's ‘544 Patent Injunction Motion has No Impact on CareDx's ...

 craig-hallum-maintains-buy-on-caredx-raises-price-target-to-22

Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $15 to $22.

 caredx-presents-findings-from-the-shore-study-heartcare-outperforms-dd-cfdna-alone-in-identifying-rejection-and-patients-experienced-fewer-biopsies

HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular RejectionCardiologists Performed the Fewes...

 hc-wainwright--co-reiterates-neutral-on-caredx

HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.

 raymond-james-downgrades-caredx-to-market-perform

Raymond James analyst Andrew Cooper downgrades CareDx (NASDAQ:CDNA) from Outperform to Market Perform.

 goldman-sachs-maintains-buy-on-caredx-raises-price-target-to-14

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $10 to $14.

 stephens--co-maintains-overweight-on-caredx-raises-price-target-to-18

Stephens & Co. analyst Mason Carrico maintains CareDx (NASDAQ:CDNA) with a Overweight and raises the price target from $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION